Search

Your search keyword '"A. Lucchi"' showing total 32 results
Start Over Author "A. Lucchi" Language french
32 results on '"A. Lucchi"'

6. [Congenitally missing maxillary lateral incisors: long-term periodontal and functional evaluation after orthodontic space closure with first premolar intrusion and canine extrusion]

Author

Björn U. Zachrisson, Simona Ferrari, Alberto Caprioglio, Marco Rosa, and Patrizia Lucchi

Subjects
Male, Cuspid, Adolescent, Tooth Movement Techniques, Dentistry, Orthodontics, Tooth mobility, Orthodontic Space Closure, Cohort Studies, 03 medical and health sciences, Young Adult, 0302 clinical medicine, stomatognathic system, Alveolar Process, medicine, Premolar, Periodontal Pocket, Orthodontic Extrusion, Humans, Gingival Recession, Maxillary central incisor, Bicuspid, Gingival recession, Anterior teeth, Anodontia, Retrospective Studies, business.industry, Dental Plaque Index, 030206 dentistry, Temporomandibular Joint Disorders, medicine.disease, Molar, Radiography, Incisor, stomatognathic diseases, medicine.anatomical_structure, Agenesis, Female, Bone Remodeling, Periodontal Index, Tooth Mobility, medicine.symptom, business, 030217 neurology & neurosurgery, Follow-Up Studies
Abstract

Introduction The aims of this investigation were to evaluate associations between orthodontic space closure (including first premolar intrusion and canine extrusion for esthetic reasons) and periodontal tissue deterioration over a 10-year period in subjects with one or both missing maxillary lateral incisors and to investigate the occurrence of signs or symptoms of temporomandibular disorder (TMD). Methods This was a retrospective cohort study comprising patients treated by the same orthodontist. The agenesis group included 26 consecutive adolescent and young adult patients (9 male, 17 female) treated with space closure. The control group consisted of 32 orthodontic patients (12 male, 20 female) with no missing teeth and no need for extractions. In the agenesis group, full-mouth probing pocket depths and bleeding on probing were recorded at 6 locations for each of 657 teeth (3942 periodontal sites). In the control group, comparative data were collected for the maxillary first molars, premolars, canines, and lateral incisors, a total of 264 teeth (1584 periodontal sites). Mobility and gingival recession were also evaluated. Patients in both groups completed questionnaires concerning symptoms related to TMD. Results The full-mouth assessments in the agenesis group generally demonstrated periodontally healthy conditions, with probing depths below 4 mm and few bleeding sites. Some slight recessions were found, mostly on molars and second premolars, and there was normal mobility of first premolars that substituted for canines. Comparisons between the agenesis and control groups showed no statistically significant differences for the maxillary teeth regarding increased pocket depth (≥4 mm) or increased mobility. Interproximal sites in the agenesis group showed less bleeding on probing than in the control group; this was statistically significant. Anterior teeth in the agenesis group did not show any more recession than in the controls. In addition, we observed no difference in signs or symptoms between the 2 groups; this might be due to the limited sample size or the drawbacks of the surveys of TMD through subjects' recall. Thus, the long-term periodontal tissue health and the incidence of dysfunction or TMD signs were similar in the space-closure agenesis group and in the control group of nonextraction orthodontic patients. Conclusions Orthodontic space closure including first premolar intrusion and canine extrusion in patients with missing lateral incisors does not incur risks for periodontal tissue deterioration or TMD in the long term.

Published
2018

8. Ricania speculum, un novel hemiptere en Mediterranee

Author

Rossi, Elisabetta and Lucchi, Andrea

Subjects
Ricania speculum, biologie, insectes, ravageurs, plantes-hôtes, Bioagresseurs, Bioagresseurs, insectes, ravageurs, Ricania speculum, biologie, plantes-hôtes
Published
2016

9. Identification clinique par spectrométrie de masse MALDI-TOF des champignons filamenteux : construction de banques de données pour les dermatophytes et les Fusarium

Author

Geraldine Lucchi, David Rageot, Sorez, M., Marc Sautour, Frédéric Dalle, Caillot, D., Ducoroy, P., ProdInra, Migration, Clinical Innovation Proteomic Platform, Partenaires INRAE, Agroécologie [Dijon], Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Hématologie clinique, CHU Lyon, and Société Française de Spectrométrie de Masse (SFSM). FRA.

Subjects
MALDI-TOF, [SDV] Life Sciences [q-bio], [SDE] Environmental Sciences, dermatophytes, [SDV]Life Sciences [q-bio], [SDE]Environmental Sciences, champignons filamentaux, [SDV.BV]Life Sciences [q-bio]/Vegetal Biology, [SDV.BV] Life Sciences [q-bio]/Vegetal Biology, fusarium
Published
2015

10. Predictive toxicology: the paths of the future

Author

Detilleux, Ph, Vallier, L, Legallais, C, Leclerc, E, Prot J, M, Choucha, L, Baudoin, R, Dufresne, M, Gautier, A, Carpentier, B, Mansuy, D, Pery, Alexandre R.R., Brochot, C, Manivet, Ph, Rabilloud, Thierry, Spire, C, Coumoul, Xavier, Junot, Ch, Laprevote, O, Le Pape, A, Tourneur, E, Ben Mkaddem, S, Chassin, C, Aloulou, M, Goujon J, M, Hertif, A, Ouali, N, Vimont, S, Monteiro, R, Rondeau, E, Elbim, C, Werts, C, Vandewalle, A, Pedruzzi, E, Coant, N, Bens, M, Cluzeaud, F, Ogier-Denis, E, Pongnimitprasert, N, Babin-Chevaye, C, Fay, M, Bernard, M, Dupuy, C, Ei Benna, J, Gougerot-Pocidale M, A, Braut-Boucher, F, Pinton, Philippe, Lucioli, Joelma, Tsybulskyy, D, Joly, Baptiste, Laffitte, J, Bourges-Abella, N, Oswald, Isabelle P., Kolf-Clauw, Martine, Pierre, St, Bats A, S, Chevalier, Aline, Bui L, Ch, Ambolet-Camoit, A, Garlatti, M, Aggerbeck, M, Barouki, R, Al Khansa, I, Blanck, O, Guillouzo, A, Bars, R, Rouas, C, Bensoussan, H, Suhard, D, Tessier, C, Grandcolas, L, Pallardy, M, Gueguen, Y, Sparfel, L, Pinel-Marie M, L, Boize, M, Koscielny, S, Desmots, S, Fardel, O, Alvergnas, M, Rouleau, A, Lucchi, G, Mantion, G, Heyd, B, Richert, L, Ducoroy, P, Martin, H, Val, St, Martinon, L, Cachier, H, Yahyaoui, A, Marfaing, H, Baeza-Squiban, A, Martin-Chouly, Corinne, Bonvallet, M, Morzadec, C, Vernhet, L, Baverel, G, El Hage, M, Nazaret, R, Conjard-Duplany, A, Ferrier, B, Martin, G, Legendre, A, Lecomte, Anthony, Froment, P, Habert, R, Lemazurier, E, Robinel, F, Dupont, O, Sanfins, E, Dairou, J, Chaffotte A, F, Busi, F, Rodrigues Lima, F, Dupret J, M, Mayati, A, Le Ferrec, Eric, Levoin, N, Paris, H, Uriac, Ph, N'Diaye, M, Lagadic-Gossmann, D, Assemat, E, Boublil, L, Borot M, C, Marano, F, Martiny V, Y, Moroy, G, Badel, A, Miteva M, A, Hussain, S, Ferecatu, I, Borot, C, Andreau, K, Boland, S, Leroux, M, Zucchini-Pascal, Nathalie, Peyre, L, Rahmani, Roger, Buron, N, Porcedou, M, Fromenty, B, Borgne-Sanchez, A, Rogue, A, Claude, N, Le Guével, Rémy, Institut National de l'Environnement Industriel et des Risques (INERIS), Laboratoire pharmaceutique Biologie Servier, Biologie Servier, Pharmacologie, toxicologie et signalisation cellulaire (U747), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Faculté de Médecine Xavier Bichat, Centre de recherche biomédicale Bichat-Beaujon (CRB3), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de recherche Pharmacologie-Toxicologie (UPT), Institut National de la Recherche Agronomique (INRA), Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire (T3S - UMR_S 1124), Cytokines, chimiokines et immunopathologie, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Fonctions et dysfonctions épithéliales - UFC (EA 4267) (FDE), Université de Franche-Comté (UFC), Plate-forme Protéomique CLIPP - Clinical and Innovation Proteomic Platform [Dijon] (CLIPP), Franche-Comté Électronique Mécanique, Thermique et Optique - Sciences et Technologies (UMR 6174) (FEMTO-ST), Université de Franche-Comté (UFC)-Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM)-Université de Technologie de Belfort-Montbeliard (UTBM)-Université de Franche-Comté (UFC)-Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM)-Université de Technologie de Belfort-Montbeliard (UTBM)-Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon] (ICMUB), Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS)-Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] (LSCE), Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Centre National de la Recherche Scientifique (CNRS), Cellules Souches et Radiations (SCSR (U967 / UMR-E_008)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris-Sud - Paris 11 (UP11), Laboratoire Bioprojet, Institut des Sciences Chimiques de Rennes (ISCR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Ecole Nationale Supérieure de Chimie de Rennes-Centre National de la Recherche Scientifique (CNRS), Unité de Biologie Fonctionnelle et Adaptative (BFA (UMR_8251 / U1133)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Mitologics SAS, Hôpital Robert Debré, Biomécanique et Bioingénierie (BMBI), Université de Technologie de Compiègne (UTC)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de radiotoxicologie expérimentale (IRSN/DRPH/SRBE/LRTOX), Service de RadioBiologie et d'Epidémiologie (IRSN/DRPH/SRBE), Institut de Radioprotection et de Sûreté Nucléaire (IRSN)-Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université de Technologie de Belfort-Montbeliard (UTBM)-Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Technologie de Belfort-Montbeliard (UTBM)-Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon] (ICMUB), Université de Bourgogne (UB)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Bourgogne (UB)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Stabilité génétique, Cellules Souches et Radiations (SCSR (U_967)), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Ecole Nationale Supérieure de Chimie de Rennes (ENSCR)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Paris 5 (UPD5)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), Université de Technologie de Belfort-Montbeliard (UTBM)-Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Technologie de Belfort-Montbeliard (UTBM)-Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon] (ICMUB), Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Ecole Nationale Supérieure de Chimie de Rennes (ENSCR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA), Université Paris-Sud - Paris 11 (UP11)-Université Paris Diderot - Paris 7 (UPD7)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Chimie de Rennes-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES), Institut National de l'Environnement Industriel et des Risques ( INERIS ), Physiologie Cellulaire des Regulations Hormonales, Nutritionnelles et Pharmacologiques, Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de recherche biomédicale Bichat-Beaujon ( CRB3 ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Unité de recherche Pharmacologie-Toxicologie ( UPT ), Institut National de la Recherche Agronomique ( INRA ), Toxicologie, Pharmacologie et Signalisation Cellulaire ( U1124 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de biostatistique et d'épidémiologie ( SBE ), Institut Gustave Roussy ( IGR ) -Institut Gustave Roussy ( IGR ), Institut de recherche, santé, environnement et travail ( Irset ), Université d'Angers ( UA ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -École des Hautes Études en Santé Publique [EHESP] ( EHESP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ) -Université des Antilles ( UA ), Fonctions et dysfonctions épithéliales - UFC (EA 4267) ( FDE ), Université de Franche-Comté ( UFC ), Plate-forme Protéomique CLIPP - Clinical and Innovation Proteomic Platform [Dijon] ( CLIPP ), Franche-Comté Électronique Mécanique, Thermique et Optique - Sciences et Technologies (UMR 6174) ( FEMTO-ST ), Université de Franche-Comté ( UFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Ecole Nationale Supérieure de Mécanique et des Microtechniques ( ENSMM ) -Université de Technologie de Belfort-Montbeliard ( UTBM ) -Université de Franche-Comté ( UFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Ecole Nationale Supérieure de Mécanique et des Microtechniques ( ENSMM ) -Université de Technologie de Belfort-Montbeliard ( UTBM ) -Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon] ( ICMUB ), Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] ( LSCE ), Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Centre National de la Recherche Scientifique ( CNRS ), Cellules Souches et Radiations ( SCSR - U 967 ), Université Paris-Sud - Paris 11 ( UP11 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut des Sciences Chimiques de Rennes ( ISCR ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Ecole Nationale Supérieure de Chimie de Rennes-Institut National des Sciences Appliquées ( INSA ) -Centre National de la Recherche Scientifique ( CNRS ), Biologie Fonctionnelle et Adaptative ( BFA ), and Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS )

Subjects
[ SDV ] Life Sciences [q-bio], [SDV.TOX]Life Sciences [q-bio]/Toxicology, [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
2010

11. Toxicologie predictive: les voies du futur

Author

Ph Detilleux, Vallier, L., Legallais, C., Leclerc, E., M Prot J, Choucha, L., Baudoin, R., Dufresne, M., Gautier, A., Carpentier, B., Mansuy, D., Pery, Alexandre R. R., Brochot, C., Ph Manivet, Thierry Rabilloud, Spire, C., Xavier Coumoul, Ch Junot, Laprevote, O., Le Pape, A., Ronan Le Guével, Tourneur, E., Ben Mkaddem, S., Chassin, C., Aloulou, M., M Goujon J, Hertif, A., Ouali, N., Vimont, S., Monteiro, R., Rondeau, E., Elbim, C., Werts, C., Vandewalle, A., Pedruzzi, E., Coant, N., Bens, M., Cluzeaud, F., Ogier-Denis, E., Pongnimitprasert, N., Babin-Chevaye, C., Fay, M., Bernard Fromenty, Dupuy, C., Ei Benna, J., A Gougerot-Pocidale M, Braut-Boucher, F., Ph Pinton, Lucioli, J., Tsybulskyy, D., Baptiste Joly, Laffitte, J., Bourges-Abella, N., P Oswald I, Kolf-Clauw, M., St Pierre, S Bats A, Aline Chevalier, Ch Bui L, Ambolet-Camoit, A., Garlatti, M., Aggerbeck, M., Barouki, R., Al Khansa, I., Blanck, O., Guillouzo, A., Bars, R., Rouas, C., Bensoussan, H., Suhard, D., Tessier, C., Grandcolas, L., Pallardy, M., Gueguen, Y., Sparfel, L., L Pinel-Marie M, Boize, M., Koscielny, S., Desmots, S., Fardel, O., Alvergnas, M., Rouleau, A., Lucchi, G., Mantion, G., Heyd, B., Richert, L., Ducoroy, P., Martin, H., St Val, Martinon, L., Cachier, H., Yahyaoui, A., Marfaing, H., Baeza-Squiban, A., Corinne Martin-Chouly, Bonvallet, M., Morzadec, C., Vernhet, L., Baverel, G., El Hage, M., Nazaret, R., Conjard-Duplany, A., Ferrier, B., Martin, G., Legendre, A., Lecomte, A., Froment, P., Habert, R., Lemazurier, E., Robinel, F., Dupont, O., Sanfins, E., Dairou, J., F Chaffotte A, Busi, F., Rodrigues Lima, F., M Dupret J, Mayati, A., Eric Le Ferrec, Levoin, N., Paris, H., Ph Uriac, Diaye, M. N., Lagadic-Gossmann, D., Assemat, E., Boublil, L., C Borot M, Marano, F., Y Martiny V, Moroy, G., Badel, A., A Miteva M, Hussain, S., Ferecatu, I., Borot, C., Andreau, K., Boland, S., Leroux, M., Zucchini-Pascal, N., Peyre, L., Rahmani, R., Buron, N., Porcedou, M., Fromenty, B., Borgne-Sanchez, A., Rogue, A., Claude, N., and Jonchère, Laurent

Subjects
[SDV] Life Sciences [q-bio], [SDV.TOX] Life Sciences [q-bio]/Toxicology
Published
2010

12. [Towards a standardization of the tools for the studies of clinical proteomics]

Author

Géraldine, Lucchi, Jean-Baptiste, Hendra, Delphine, Pecqueur, and Patrick, Ducoroy

Subjects
Proteomics, Reproducibility of Results, Reference Standards, Body Fluids, Neoplasm Proteins, Specimen Handling, Neoplasms, Sample Size, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Calibration, Biomarkers, Tumor, Humans, Multicenter Studies as Topic, Blood Chemical Analysis
Abstract

Proteins identified in biological fluids of cancer patients could be helpful for both diagnosis and prognosis. However, clinical proteomics based on analysis of protein profiles in biological fluids has demonstrated various flaws, most of them related to the difficulties met in reproducibility. These difficulties could be partly overcome by accurate standardisation of pre-analytical and analytical steps of these studies. The size of the patient cohort is one of the parameters that determine the powerfulness of the study. Recruitment of a cohort with a sufficient size often implies multicentric studies in which analysis of the reproducibility between centres and standardisation of pre-analytical and analytical steps are essential. Such a standardisation requires the use of calibrated samples as common references.

Published
2007

14. [Hormone replacement therapy in breast cancer patients: a study of 230 patients, with a case-control study]

Author

A, Gorins, M, Espié, N, Bedairia, F, Perret, B, Tournant, H, Novak, E, Lucchi-Angelier, and M, Marty

Subjects
Adult, Contraindications, Estrogen Replacement Therapy, Breast Neoplasms, Middle Aged, Case-Control Studies, Quality of Life, Humans, Female, Prospective Studies, Menopause, Neoplasm Metastasis, Neoplasm Recurrence, Local, Aged
Abstract

After recalling the classical contra-indication of hormone replacement therapy (HRT) concerning patients with a personal history of breast cancer (BC), and arguments that may be opposed, the authors report the present results of a prospective study undertaken in the Center of Breast Diseases in Saint-Louis hospital in Paris since February 1992.By April 2001, 230 patients had been included. A free interval of 2 years at least since the treatment of the primary BC has been observed. The reasons for prescribing HRT were vasomotor troubles (flushes, nightly sweats) or a dyspareunia, which were severe and not controlled by non-hormonal treatments. There was also an indication of a major osteoporotic or cardiovascular danger. In fact, many of these patients had a premature, artificial, chemo-induced menopause. The HRT most often used was an estro-progestin association (estradiol + a progestin compound) given either continuously or with a 5-d interruption each month. The mean duration of treatment was 2.5 years.Results, concerning the improvement of menopause troubles, were remarkable in the great majority of troubles. HRT had to be stopped in 39 cases, reading as follows: 17 cases for relapses (seven local, six in the contro-lateral breast and four metastases (7%)). Also, 22 patients (9%) interrupted their HRT for serious side-effects. A case-control study did not show any significant difference between with and without HRT patients concerning the overall survival without relapse.Quality of life of patients was often substantially improved, and a deleterious effect on the cancer disease was not found. Our results are in agreement with the literature from other countries. However, one must be cautious. In such circumstances, HRT must be prescribed with the informed consent of the patients and delivered in appropriate hospital and university centers. It is wished that large randomised prospective studies may be undertaken.

Published
2003

15. [Patients' rights during medical research and specifics in oncology (in France)]

Author

E, Lucchi-Angellier

Subjects
Clinical Trials as Topic, Patient Rights, Humans, Ethics, Medical, France, Patient Advocacy, Medical Oncology
Abstract

Clinical research in oncology is part of the care, instead of being theoretical, because it can offer new drugs to patients who are suffering from severe illnesses, but also because it offers better practices. The vulnerability of patients suffering from cancers, at each stage of the disease, requires special protection. Because of its multiple aspects, clinical research in oncology asks ethical questions. Medical deontology and laws, national and supranational, allow research with respect to the subject. The present article reviews these texts.The rights of the person involved in clinical trials essentially consist of information and consent, but also the right to refuse, and the confidentiality of data collected. More subtle rights are now emerging because of new technologies, such as genetics. One of them is the right to be protected as a member of the human race, which is in continuity with human rights.Finally, medical responsibility during research is increasing. It responds to the right of each person to see that his dignity is respected, although this dignity may be difficult to define. One of the more pertinent questions in building 'evidence-based ethics' concerns research into the evaluation by the persons themselves involved in the research.

Published
2002

16. [Hormone therapy and breast cancer: a review]

Author

E, Lucchi-Angellier

Subjects
Adult, Selective Estrogen Receptor Modulators, Time Factors, Adolescent, Antineoplastic Agents, Hormonal, Breast Neoplasms, Meta-Analysis as Topic, Risk Factors, Animals, Humans, Prospective Studies, Aged, Randomized Controlled Trials as Topic, Retrospective Studies, Postoperative Care, Aromatase Inhibitors, Estrogen Replacement Therapy, Estrogen Antagonists, Middle Aged, Tamoxifen, Clinical Trials, Phase III as Topic, Chemotherapy, Adjuvant, Female, Menopause, Neoplasm Recurrence, Local, Follow-Up Studies
Abstract

Tamoxifen as adjuvant hormonal therapy after hormonosensitive-breast cancer surgery is well established nowadays, as well as its efficacy in first-line therapy of advanced hormonosensitive breast cancers. Research of drugs which could be effective, with little toxicity, and having a positive impact on cardiovascular disease or bone is an important issue.New drugs are in development or will soon be on the market to permit second or third lines of treatment with respect to effectiveness and quality of life, such as new anti-estrogens or selective estrogen receptors modulators or aromatase inhibitors. Their principal characteristics are reviewed through recent data.Prevention of breast cancer is a pertinent question and major publications are presented. Finally, the controversy about the possible reintroduction of replacement hormonal therapy after breast cancer will be questioned through trials.

Published
2002

17. [Is clinical diagnosis of deep venous thrombosis really unreliable?]

Author

M, Lucchi and S, Bilancini

Subjects
Adult, Aged, 80 and over, Male, Adolescent, Predictive Value of Tests, Humans, Female, Middle Aged, Thrombophlebitis, Child, Sensitivity and Specificity, Aged
Abstract

The clinical diagnosis of deep venous thrombosis (DVT) is traditionally regarded as lacking of sensitivity and specificity. As we were not fully convinced by this statement, we assessed the value of two associated clinical signs in outpatients, namely the flapping of the calf and the modified Lowemberg's sign. The examiner has first put forth a diagnosis based on the data of history and/or the presence of clinical signs specific for another kind of disease. Then an objective test of the diagnosis was carried out with a duplex scanner performed by an expert. DVT was observed in 39 subjects out of 102 (38.2%) who where all referred by general practitioners (GP), which confirms the poor diagnostic value of clinics at GP level. Associated positiveness of these two signs yielded 87.2% sensitivity and 88.8% specificity with a positive predictive value of 82.9% and a negative predictive value of 91.8%. The addition of an overall clinical assessment later improved results to 87.2% sensitivity and 96.8% specificity, a positive predictive value of 94.4% and a negative predictive value of 92.4%. In this study, the performance of clinics, if assessed by an angiologist qualified for the diagnosis of DVT, proved to be better than in the common data of the literature. Clinical data, if perfect, should be included in the diagnostic management of DVT.

Published
1993

18. [Leukocyte entrapment in chronic venous stasis: myth or reality?]

Author

S, Bilancini, M, Lucchi, S, Tucci, A, Fochetti, G, Cirillo, and A, Aiello

Subjects
Male, Platelet Count, Cellulitis, Postphlebitic Syndrome, Thrombophlebitis, Capillaries, Varicose Ulcer, Varicose Veins, Leukocyte Count, Hematocrit, Venous Insufficiency, Chronic Disease, Erythrocyte Count, Leukocytes, Humans, Female
Published
1992

19. [Sclerotherapy of the internal saphenous vein: comparison between the trombovar protocol and the trombovar-iodine protocol]

Author

S, Bilancini, M, Lucchi, and S, Tucci

Subjects
Sodium, Iodides, Sodium Tetradecyl Sulfate, Varicose Veins, Drug Combinations, Italy, Recurrence, Sclerotherapy, Humans, Drug Therapy, Combination, Saphenous Vein, Benzyl Alcohols, Retrospective Studies, Ultrasonography
Abstract

Sclérosing injections of the long saphenous vein involve different protocols concerning technique as well as the sclerosing fluids and doses used. This retrospective study involved comparison of two groups of patients treated during successive periods on the basis of a protocol consisting of 3 per cent Trombovar at doses increasing progressively up to a maximum of 6 and another protocole as follows: 3 per cent Trombovar, 1 ml; 3 per cent Trombovar 2 ml; 8 per cent Variglobine 2 ml; 12% Variglobine 2 ml; 12 per cent Variglobine 3 ml; "Overdose" (12 per cent Variglobine 6 ml + 3 per cent Trombovar 6 ml, i.e. 2-4 ml as divided doses. Patients were seen for follow-up evaluation by continuous wave Doppler after six months and two years. The first protocole, with a mean follow-up of 11.5 months, was associated with a 40 per cent recurrence rate. The rate for the second, with a mean follow-up of 13.5 months, was 15.87 per cent. The difference between these figures was statistically very significant (p approximately 0.001). The largest amounts of sclerosing fluid provided lower percentage recurrence rates compared relatively small amounts.

Published
1992

20. [Pigmented livedo. Histologic design and pathogenetic hypothesis]

Author

S, Bilancini, P, Gallo, P, Bernucci, G, d'Amati, and M, Lucchi

Subjects
Adult, Vasculitis, Humans, Melanocytes, Female, Keratosis, Telangiectasis, Epidermis, Middle Aged, Pigmentation Disorders, Aged, Skin
Abstract

Pigmented livedo is a frequently encountered disease. It occurs as an ochre reticular membrane which does not disappear when the limb is raised. It is characteristic in persons who already have livido reticularis and who expose themselves for several hours every day to the heat from chimneys or foot-warmers. We wanted to study the histological context of this disease in a group of female patients that we kept under observation. The data that we compiled showed that it is due to lymphocytic vasculitis accompanied by atrophy of the epidermis, hyperpigmentation of the basal keratinocytes and telangiectasia. Our pathogenetic hypothesis is that it involves vasculitis "a calore", with atrophy of the epidermis, telangiectasia and melanoid pigmentation, which is the cause of the characteristic brown pigmentation.

Published
1990

22. [Danazol and antithrombin III deficiency]

Author

M, Lucchi and S, Bilancini

Subjects
Male, Antithrombin III Deficiency, Danazol, Pregnadienes, Drug Evaluation, Humans, Female, Middle Aged
Abstract

The study concerned 7 subjects (3 men, 4 women) with nonfamilial antithrombin III deficit which, in the absence of known causes of acquired deficiency, was defined as "sporadic". Danazol (an attenuated synthetic androgen) already shown to be capable of compensating for a lack of certain antiproteases, was given in doses of 200 mg 3 times per day for 10 days, resulting in a rapid rise (mean 21.2%) in antithrombin III values. Unlike results reported in the literature in cases of familial antithrombin III deficit, the levels did not drop below their initial values despite discontinuance of the drug but unexpectedly remained high and even shows a slight subsequent rise. Although our study was limited to 11 cases, these data seem worthy of being reported, with the prospect of other confirmations concerning either this sort of "sporadic" antithrombin III deficit or the favorable effect of Danazol, even at long term.

Published
1990

23. Choses trouvées, choses pensées.

Author

Gianikian, Yervant and Ricci Lucchi, Angela

Abstract

The article presents some of the notes made by the authors during their search for World War I images for their film "Oh! Uomo," directed by Yervant Gianikian and Angela Ricci Lucchi.

Published
2004

24. ['Depletion' in the treatment of lymphedema of the lower extremities]

Author

S, Bilancini and M, Lucchi

Subjects
Adult, Aged, 80 and over, Male, Leg, Adolescent, Middle Aged, Combined Modality Therapy, Exercise Therapy, Furosemide, Humans, Female, Lymphedema, Bed Rest, Aged
Abstract

The treatment of lymphedemas consists of two phases: reduction of the edema-prevention of its recurrence. The second phase is invariably linked to the use of a strong contention by means of a stocking. In order to reduce the edema, opinions do not all occur. Some advocate pressotherapy, manual lymphatic drainage, wrapping and immersion in mercury. The authors propose another form of treatment which has the merit to be simple and well tolerated. Their study is based on 187 cases of moderate lymphedema of the lower extremities and, they observed favorable results in 179 patients. For 8 patients, there were partial results, but the treatment prescribed had not been perfectly followed by the patients.

Published
1987

25. [Microcirculatory changes in Bureau-Barrière disease and alcoholic polyneuropathy. Preliminary note: correlations and pathogenic hypotheses]

Author

S, Bilancini, M, Lucchi, and S B, Curri

Subjects
Adult, Male, Alcoholism, Microcirculation, Humans, Peripheral Nervous System Diseases, Middle Aged, Nervous System Diseases, Aged
Abstract

Nosologically, in ulcerative-mutilating acropathies (U.M.A.), it is customary to differentiate the usual forms of the disease (Thevenard's disease) which develop primarily and the secondary forms (U.M.A. or, better, pseudo-U.M.A.), in which the syndrome is secondary to a known pathologic process and which represent a symptom and not a disease. The link between these two nosological entities is the pseudo-syringomyeli U.M.A. of the lower extremities, or Bureau-Barrier's disease. This disease is exclusively seen in alcoholics and is similar to the neurological alterations observed in alcoholic polyneuropathies. Some authors consider this form as an ulcerative-mutilating acropathy (symptomatic U.M.A.). The objective of our research is to demonstrate the similarity between the microcirculation alterations in patients with Bureau-Barriere's disease and patients with alcoholic polyneuropathy without trophic lesions. For this purpose, we have biopsied the pulp of the great toe, according to the method described by Curri-Schendorf in three patients with Bureau-Barriere's disease, 46, 50 and 65 year-old respectively, and three patients with alcoholic polyneuropathy, 34, 54 and 63 years-old respectively. All these patients presented a normal macrocirculation, without any diabetes, nor disease prone to alter the microcirculation. The results obtained, in a limited series however, permit to state that it is possible to unify alcoholic polyneuropathy and Bureau-Barriere's disease in a single clinical and nosological entity, and to say that the latter only represents an evolution of the former. Besides, we have notices that microcirculation alterations, although non-specific, are extensive and occur early, permitting to suspect a pathogenic process related to a true alcoholic histo-angeitis which, for us, represent the pathogenic basis of Bureau-Barriere's disease.

Published
1988

26. [Hemicrania and vascular acrosyndromes--is there a correlation? Observations on 739 patients]

Author

S, Bilancini and M, Lucchi

Subjects
Adult, Male, Leg, Adolescent, Venous Insufficiency, Migraine Disorders, Arm, Humans, Arterial Occlusive Diseases, Female, Middle Aged, Child, Aged
Abstract

The purpose of this article was to verify whether there was a clinical correlation between hemicrania - a pathological process for which a vasomotor component is advocated - and vascular acrosyndromes - above all, a vasomotor pathological process.

Published
1988

27. [X-ray images in mucopolysaccharidoses]

Author

A, Lucchi, C, Montanelli, L, De Florio, and R, Canini

Subjects
Radiography, Bone Diseases, Developmental, Humans, Mucopolysaccharidoses
Published
1975

28. En dehors des camps.

Author

Koscalova, Alena, Lucchi, Elena, and Kampmüller, Sabine

Published
2010

29. Outside camp settings

Author

Alena Koscalova, Elena Lucchi, and Sabine Kampmüller

Subjects
forced migration, refugee, displacement, DRC, Social history and conditions. Social problems. Social reform, HN1-995
Abstract

Current assessment tools and intervention strategies are based mainly on experience of camp-like situations; what is needed are innovative responses to address problems specific to open settings.

Published
2010

31. [X-ray images in mucopolysaccharidoses].

Author

Lucchi A, Montanelli C, De Florio L, and Canini R

Subjects
Bone Diseases, Developmental etiology, Humans, Radiography, Bone Diseases, Developmental diagnostic imaging, Mucopolysaccharidoses diagnostic imaging
Published
1975

Catalog

Books, media, physical & digital resources
See catalog results